Site Search
Professionals 967 results
Capabilities 89 results
Practice Area
Trial skills matter—even in a world where few disputes ever see the inside of a courtroom. Winston has built a reputation as a trial lawyers’ firm, featuring seasoned litigators who leverage extensive courtroom experience to meet our clients’ business and legal objectives. Our long history of taking cases to trial—and winning—provides our clients with tremendous settlement leverage with their adversaries, as well as a substantial likelihood of a favorable resolution if, and when, they go to trial.
Industry
Insurance plays an essential role in risk mitigation for financial services companies. As risks evolve, questions often arise concerning the scope of insurance coverage and the interpretation and application of policy provisions. Winston’s insurance lawyers provide companies with best-in-class advice, corporate and transactional counsel, and, if need be, litigation defense in high-stakes coverage disputes and class actions. We have achieved excellent outcomes for our clients in matters involving a wide variety of insurance policies and claims, including cybersecurity, travel, long-term care, and annuities, among others. Moreover, we have experience in emerging issues and industries, such as blockchain technology and artificial intelligence, both of which present insurers with a unique and complicated set of risks and opportunities.
Industry
Experience 499 results
Experience
|May 2, 2025
Copley Acquisition Corp. Closes $172.5 Million Initial Public Offering
Experience
|April 29, 2025
Stream Realty Completes Ownership Transfer of Houston Center
Experience
|April 23, 2025
Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination
Insights & News 6,666 results
Sponsorship
|May 28, 2025
Winston & Strawn Sponsors SBIA’s 2025 Midwest Deal Summit
Winston & Strawn is proud to be an elite sponsor for the Small Business Investor Alliance’s (SBIA) 2025 Midwest Deal Summit on May 28-29, 2025, in Chicago.
The Reg E Reader
|May 27, 2025
|4 Min Read
Since President Trump took office, the administration has substantially curtailed the Consumer Financial Protection Bureau’s (Bureau) rulemaking and enforcement activity.
Client Alert
|May 23, 2025
|10+ Min Read
One Big Beautiful Bill: Proposed Tax Changes Clear House and Proceed to Senate
On Thursday, May 22, 2025, Republicans in the House of Representatives passed the One Big Beautiful Bill Act (the Act), advancing proposed changes to the tax law that could significantly impact individuals and businesses. The Act extends several flagship provisions of the 2017 Tax Cuts and Jobs Act (TCJA) and reflects certain campaign promises made by President Trump. In doing so, the Act raises excise taxes on certain tax-exempt organizations, eliminates many of the clean energy tax credits first introduced by the 2022 Inflation Reduction Act, and provides for a $4 trillion increase on the national debt limit.[1] Despite prior indications to the contrary, the Act does not address the treatment of carried interest. The Congressional Budget Office estimates that the cumulative effect of the Act’s changes to the tax law will result in an increase to the federal deficit of approximately $3.8 trillion. The Act now heads to the Senate for consideration.
Other Results 130 results
Law Glossary
What Is the Patent Trial and Appeal Board?
The Patent Trial and Appeal Board (PTAB) is a tribunal within U.S. Patent and Trademark Office. The PTAB oversees trial proceedings, namely: inter partes review (IPR), post-grant review (PGR), covered business method (CBM) review, and derivation proceedings. The Board also hears appeals from adverse patentability decisions by patent examiners in original applications, reissues, and reexaminations. And, while phasing out since the passage of the America Invents Act (AIA) in 2011, the PTAB is also responsible for deciding interferences. The PTAB was previously referred to as the Board of Patent Appeals and Interferences and was renamed by the AIA.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)